ReviewPharmacogenomics2013
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
Review in Pharmacogenomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review.Clinical and translational science · 2023Pooled it
- Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.The pharmacogenomics journal · 2017Pooled it
- Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.Advances in therapy · 2016Pooled it
- The Three Musketeers in Cancer Therapy: Pharmacokinetics, Pharmacodynamics and Personalised Approach.Journal of personalized medicine · 2025Review
- Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications.Cancers · 2025Review
- Is There an Interplay between Environmental Factors, Microbiota Imbalance, and Cancer Chemotherapy-Associated Intestinal Mucositis?Pharmaceuticals (Basel, Switzerland) · 2024Article
- Clinical Strategies in Gene Screening Counseling for the Healthy General Population.Korean journal of family medicine · 2024Article
- Pharmacogenetics of Anticancer Drugs: Clinical Response and Toxicity.Cancer treatment and research · 2023Article
- A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Genetic Variations of theJournal of personalized medicine · 2022Article
- Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.Frontiers in pharmacology · 2022Article
- PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge.Current protocols · 2021Article
- DDA-SKF: Predicting Drug-Disease Associations Using Similarity Kernel Fusion.Frontiers in pharmacology · 2021Review
- Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations.Pharmaceutics · 2020Article
- Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD).International journal of molecular sciences · 2020Review
- Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.International journal of molecular sciences · 2020Review
- A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.Contemporary clinical trials · 2020Article
- The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics.Oncology and therapy · 2019Review
- Safety of Novel Targeted Therapies in Oncology.Drug safety · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the past decade, advances in pharmacogenetics and pharmacogenomics (PGx) have gradually unveiled the genetic basis of interindividual differences in drug responses. A large portion of these advances have been made in the field of anticancer therapy. Currently, the US FDA has updated the package inserts of approximately 30 anticancer agents to include PGx information. Given the complexity of this genetic information (e.g., tumor mutation and gene overexpression, chromosomal translocation and germline variations), as well as the variable level of scientific evidence, the FDA recommendation and potential action needed varies among drugs. In this review, we have highlighted some of these PGx discoveries for their scientific values and utility in improving therapeutic efficacy and reducing side effects. Furthermore, examples are also provided for the role of PGx in new anticancer drug development by revealing novel druggable targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.